We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.57B
AUM Growth
-$21.5M
Cap. Flow
+$32.3M
Cap. Flow %
1.25%
Top 10 Hldgs %
39.02%
Holding
197
New
37
Increased
49
Reduced
41
Closed
10

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$39M
2
JNJ icon
Johnson & Johnson
JNJ
+$21.2M
3
ESPR
Esperion Therapeutics
ESPR
+$13.9M
4
ABBV icon
AbbVie
ABBV
+$11.5M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$36.3M
2
AMGN icon
Amgen
AMGN
+$29.7M
3
BIIB icon
Biogen
BIIB
+$20.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$19.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.47%
2 Real Estate 2.71%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
101
DELISTED
Clovis Oncology, Inc.
CLVS
$3.98M 0.15%
75,400
– –
PBYI icon
102
Puma Biotechnology
PBYI
$402M
$3.81M 0.15%
55,985
+7,593
+16% +$569K
OVID icon
103
Ovid Therapeutics
OVID
$442M
$3.79M 0.15%
535,824
– –
BDX icon
104
Becton Dickinson
BDX
$45.6B
$3.74M 0.15%
+17,685
New +$3.87M
MASI
105
DELISTED
Masimo
MASI
$3.67M 0.14%
+41,666
New +$3.63M
ALDR
106
DELISTED
Alder Biopharmaceuticals
ALDR
$3.56M 0.14%
+279,950
New +$4.05M
NTLA icon
107
Intellia Therapeutics
NTLA
$1.55B
$3.53M 0.14%
+167,381
New +$4.12M
TRIL
108
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.37M 0.13%
468,399
+18,399
+4% +$140K
AFMD
109
DELISTED
Affimed
AFMD
$3.34M 0.13%
180,532
+40,000
+28% +$755K
RMD icon
110
ResMed
RMD
$30.3B
$3.33M 0.13%
+33,819
New +$3.2M
TSRO
111
DELISTED
TESARO, Inc.
TSRO
$3.29M 0.13%
57,595
– –
ARDX icon
112
Ardelyx
ARDX
$1.25B
$3.23M 0.13%
639,370
– –
MYOV
113
DELISTED
Myovant Sciences Ltd.
MYOV
$3.2M 0.12%
150,471
-249,529
-62% -$3.8M
ARGX icon
114
argenx
ARGX
$54.6B
$3.13M 0.12%
38,931
-7,535
-16% -$569K
PRGO icon
115
Perrigo
PRGO
$1.43B
$3.11M 0.12%
37,300
– –
BHC icon
116
Bausch Health
BHC
$2.25B
$3.06M 0.12%
192,000
– –
PTLA
117
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.94M 0.11%
+89,978
New +$3.95M
PHG icon
118
Philips
PHG
$25.8B
$2.89M 0.11%
99,248
+7,029
+8% +$209K
SNDX icon
119
Syndax Pharmaceuticals
SNDX
$1.73B
$2.85M 0.11%
200,000
– –
INVA icon
120
Innoviva
INVA
$1.57B
$2.69M 0.1%
161,603
-87,200
-35% -$1.35M
PRAH
121
DELISTED
PRA Health Sciences, Inc.
PRAH
$2.69M 0.1%
32,460
-32,460
-50% -$2.88M
TTPH
122
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.64M 0.1%
42,966
– –
BAX icon
123
Baxter International
BAX
$13.8B
$2.6M 0.1%
+39,965
New +$2.7M
ARRY
124
DELISTED
Array Biopharma Inc
ARRY
$2.55M 0.1%
+156,056
New +$2.5M
CRL icon
125
Charles River Laboratories
CRL
$11.3B
$2.42M 0.09%
22,670
-63,134
-74% -$6.81M
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Tekla Capital Management held 197 positions worth $2.57B, down 0.83% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q1 2018 filing shows 37 new, 49 increased, 41 reduced and 10 closed positions. Its largest new stake was Esperion Therapeutics: 189,287 shares worth $13.7M. The largest sale was Gilead Sciences, an estimated $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q1 2018 buy was Esperion Therapeutics: 189,287 shares worth $13.7M.
  • Tekla Capital Management added most to Pfizer in Q1 2018, an estimated $39M increase.
  • Tekla Capital Management's biggest Q1 2018 reduction was Gilead Sciences, cutting an estimated $36.3M.
  • Tekla Capital Management fully exited NuVasive, Inc. in Q1 2018, selling an estimated $6.87M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.57B portfolio in Q1 2018.
  • Tekla Capital Management opened 37 new positions and closed 10 in Q1 2018.
  • Tekla Capital Management's portfolio value fell 0.83% quarter-over-quarter to $2.57B.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.